查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1087061

肺炎球菌疫苗:市场预测(2022年～2027年)

Pneumococcal Vaccines Market - Forecasts from 2022 to 2027
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 110 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球肺炎球菌疫苗的市场规模预测将从2020年的99亿6,200万美金，在预测期间内预计将以6.97％的年复合成长率扩大，到2027年达到159亿6,300万美元。

本报告提供肺炎球菌疫苗的世界市场调查，提供市场规模和预测，市场促进因素及课题，市场趋势，各市场区隔的市场分析，竞争情形，主要企业的简介等系统性资讯。

目录

第1章 简介

  • 市场定义
  • 市场区隔

第2章 调查手法

  • 调查资料
  • 假设

第3章 摘要整理

  • 调查的重点

第4章 市场动态

  • 推动市场要素
  • 阻碍市场要素
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 新加入厂商者的威胁
    • 替代品的威胁
    • 竞争企业间的敌对关係
  • 产业的价值链分析

第5章 全球肺炎球菌疫苗市场分析:各类型

  • 简介
  • 结合型疫苗
  • 多糖类疫苗

第6章 全球肺炎球菌疫苗市场分析:各用途

  • 简介
  • 定期疫苗接种
  • 病/感染疾病的疫苗接种

第7章 全球肺炎球菌疫苗市场分析:各地区

  • 简介
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他
  • 中东和非洲
    • 沙乌地阿拉伯
    • 以色列
    • 其他
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 印尼
    • 台湾
    • 泰国
    • 其他

第8章 竞争情形与分析

  • 主要企业策略分析
  • 新兴企业与市场的有利性
  • 合併，收购，协定，及合作
  • 供应商竞争力矩阵

第9章 企业简介

  • Pfizer
  • GSK
  • Merck
  • AstraZeneca
  • Serum Institute of India Pvt Ltd
简介目录
Product Code: KSI061612059

The global pneumococcal vaccines market is projected to witness a CAGR of 6.97% during the forecast period to reach a market size of US$15.963 billion by 2027, increasing from US$9.962 billion in 2020.

Introduction

Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines. Immunization is one of the widely accepted forms against the disease.

Market Drivers.

Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death. Pneumonia vaccines are primarily given to children under two years and adults 65 years and older. The regular vaccination programs under the national policy are aiding the market to grow. Secondly, the rising awareness against pneumonia, directives launched by WHO and UNICEF, and increasing government support assist the expansion of the market in the current scenario.

By type, the pneumococcal conjugate vaccine segment is the most significant contributor to the global pneumonia vaccine market and is expected to maintain its dominant position throughout the analysis period. Geographically, the Asia-Pacific region showcases the highest growth potential due to changing health sectors and efforts led by the international organization, while North America continues to dominate the market.

Growth Factors.

  • Growing incidence of childhood pneumonia.

Among all the infectious diseases prevalent among children, pneumonia has the highest share of fatalities in children. More than 800 thousand children under the age of five lose their lives every year due to pneumonia, while the number is around 2.2 thousand per day. Around 153 thousand of those children are newborns. According to data from UNICEF, 1,400 cases per 100,000 children suffer from pneumonia every year, which makes it 1 out of 71 children. The South Asian region has the highest incidence with 2,500 cases per 100,000 children, while the West and Central African region has an incidence rate of 1,620 cases per 100,000 children. These numbers are creating an alarming situation to combat child mortality rates which is expanding the vaccines market to increase its production capacity and spread its reach.

  • Raising awareness and policies.

International organizations like WHO, UNICEF, and UNDP, in conjunction with the national government, are working to bring down the pneumonia infection rates, especially among the children and older generation who are more susceptible to such diseases. As such, the government of India launched 2017 the pneumococcal conjugate vaccine (PCV) into its national immunization program. These plans and policies boast the vaccines market with novel products being introduced and expansion of the existing product portfolios.

Restraints.

The high cost involved in the production of vaccines and the long duration of the process of production is challenging factors for market growth. However, the government subsidies on vaccine production and funds released by international organizations are helping to clear the hindrances of the path.

Impact of COVID-19 on the Pneumococcal Vaccines Market

The pandemic had an unforeseen effect on the vaccination market, and the impact on the pneumococcal vaccine market is no different. At first, routine vaccination decreased due to the pandemic. However, later studies indicated that the COVID-19 pandemic increased the need for pneumococcal vaccination, causing shipping restrictions on pneumococcal vaccines, which may cause a shortage of vaccines during a pandemic.

Competitive Insights.

The market leaders for the Global Pneumococcal Vaccines Market are Pfizer, GSK, Merck Serum Institute of India Pvt Ltd, and AstraZeneca. The recent developments by the key players include:

  • In 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) approved their pneumonia vaccine named PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine). The vaccine was developed by Pfizer for adults ages 18 years and older in order to help the body fight pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes.
  • Merck's pneumonia vaccine called VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine), which was specifically developed for adults 18 years of age and older to help the body fight Streptococcus pneumoniae serotypes, got the approval of the U.S. Food and Drug Administration (FDA)
  • In 2020, Serum Institute announced it had developed a pneumonia vaccine named PNEUMOSIL by collaborating with PATH and Bill and Melinda Gates Foundation for more than a decade.

Segmentation:

  • By Type

Conjugate vaccines

Polysaccharide vaccines

  • By Application

Routine Vaccination

Vaccination for Disease/ Infection

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Pneumococcal Vaccines Market Analysis, By Type

  • 5.1. Introduction
  • 5.2. Conjugate vaccines
  • 5.3. Polysaccharide vaccines

6. Global Pneumococcal Vaccines Market Analysis, By Application

  • 6.1. Introduction
  • 6.2. Routine Vaccination
  • 6.3. Vaccination for Disease/ Infection

7. Global Pneumococcal Vaccines Market Analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America 
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico 
    • 7.2.4. Others 
  • 7.3. South America 
    • 7.3.1. Brazil
    • 7.3.2. Argentina 
    • 7.3.3. Others
  • 7.4. Europe 
    • 7.4.1. United Kingdom
    • 7.4.2. Germany 
    • 7.4.3. France 
    • 7.4.4. Italy 
    • 7.4.5. Spain
    • 7.4.6. Others
  • 7.5. Middle East and Africa 
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel 
    • 7.5.3. Others 
  • 7.6. Asia Pacific 
    • 7.6.1. Japan
    • 7.6.2. China 
    • 7.6.3. India
    • 7.6.4. Indonesia
    • 7.6.5. Taiwan
    • 7.6.6. Thailand 
    • 7.6.7. Others 

8. Competitive Intelligence

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrative
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. Pfizer
  • 9.2. GSK
  • 9.3. Merck
  • 9.4. AstraZeneca
  • 9.5. Serum Institute of India Pvt Ltd